CD274 and neoplasm: In each of the tested models, LY3300054 treatment resulted in enhanced anti-tumor alloreactivity and robust anti-tumor effects, demonstrating the potency of the agent as well as the relevance of the PD-1/PD-L1 axis in the context of humanized mouse models.